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Significant progress in the investigation of the regulation of prostanoid formation has recently been made by cloning a second gene coding for 
prostaglandin G/H synthase (PGHS; EC 1.14.99.1). In this study we examined the expression of the two PGHS isoforms during phorbol ester 
induced monocytic differentiation of human myeloid leukemia cells (U937). Murine and ovine PGHS-I probes hybridized to 2.8- and 5.5.kb mRNA 
species, whereas the murine PGHS-2 probe hybridized to a 5.3-kb species. Western blot analysis using antisera to mouse PGHS-1 and to a synthetic 
peptide derived from a mouse PGHS-2-specific region revealed a band of 70 kDa for PGHS-1 and a doublet of about 85 kDa for PGHS-2. Unlike 
PGHS-2, which was not expressed in U937 control cells, both PGHS-1 protein and mRNA were detected in untreated U937 cells. TPA strongly 
induced PGHS-2 protein and also increased the amount of PGHS-1 protein. Correspondingly, a marked induction of PGHS-2 mRNA was found, 
but virtually no change in the expression of the PGHS-I 2.8-kb mRNA occurred. The induction of both PGHS isoforms turned out to be 
dexamethasone-sensitive. The suppression of PGHS-2 induction was more pronounced. These results suggest that both PGHS-I and to a larger 
extent PGHS-2 contribute to the upregulation of prostanoid synthesis during monocytic differentiation. 
Prostaglandin G/H synthase: Prostanoid; Monocytic differentiation; Corticosteroid 
1. INTRODUCTION 
Prostanoids are local hormones acting at or near their 
sites of synthesis in both an autocrine and paracrine 
fashion, e.g. as proinflammatory agents secreted by ac- 
tivated macrophages [1,2]. Therefore, the regulation of 
the cellular capacity to secrete prostanoids both as rapid 
response to a stimulus or slowly induced during differ- 
entiation is of great interest. 
A major regulatory step occurs at the level of PGHS. 
The enzyme has been purified from sheep seminal vesi- 
cles [3] and cDNA clones were obtained from various 
sources [4-71. These hybridize to mRNAs of about 2.8 
kb on Northern blots. Recently, a second PGHS gene 
(PGHS-2) has been cloned from sheep [8], mouse [9,10], 
and human [ 111, which hybridizes to a mRNA of about 
45 kb and is not coordinately expressed with PGHS-1 
[ 121. In human peripheral blood monocytes the PGHS-2 
gene was induced by LPS, TPA, or IL-l, while little or 
no change was observed in the expression of the 2.8-kb 
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PGHS-1 mRNA [lO,l 11. Thus the upregulation of pro- 
staglandin secretion during monocytic activation seems 
to be related to PGHS-2 induction. We were interested 
in whether changes in the induction of PGHS-2 also 
correlate with the increase in prostaglandin synthesis 
and PGHS activity observed during monocytic differen- 
tiation of human myeloid leukemia cells [ 133151. There- 
fore, the human monoblastoid cell line U937 was used 
as a model system. When treated with the phorbol ester 
12-O-tetradecanoylphorbol-13-acetate (TPA) these cells 
acquire a macrophage-like phenotype within two to 
three days [I 5-l 71. The data presented here suggest that 
the glucocorticoid-sensitive increase in prostaglandin 
synthesis and PGHS activity in TPA-treated U937 cells 
[14.15] is due to an induction of both PGHS isoforms. 
2. MATERIALS AND METHODS 
2.1. Muteridv 
Dexamethasone phosphate (Decadron) and prednisolone hemisuc- 
cinate sodium salt (Solu-Decortin H) were obtained from Merck 
Sharp and Dohme, Munchen, and progesterone was obtained from 
Sigma, Munchen. TPA (Sigma, Munchen) was kept as stock solution 
(IO-’ M) in dimethyl sulfoxide and diluted in medium immediately 
before use. 
2.2. D~&cxtiution qf’ U937 cell,r 
Cells (5 x lO’cells/ml) were cultured in RPM1 1640 medium (Gibco. 
Karlsruhe, Germany) with 5% fetal calf serum, 100 U/ml penicillin. 
100 pg_/rnl streptomycin, and 1% t_-glutamine, and differentiated with 
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5 nM TPA for 3 days. Steroids ( 10mh M) were added 4 h before the 
addition of TPA. Viability of the cells was determined by trypan blue 
exclusion. 
After sonication (3 x 10 s. 50 W) cytosol and membranes were 
obtained by differential centrifugation (10 min. 1,000 x g; 30 min. 
100,000 xg). Microsomal protein (50 pg [PGHS-I] and 100 pg 
[PGHS-21) was subjected to sodium dodecyl sulfate (SDS)-poly- 
acrylamide gel electrophoresis according to Laemmli [IS]. After elec- 
trophoresis, proteins were transferred to a nitrocellulose membrane 
(Schleicher & Schuell) by semidry blotting according to the manufac- 
turers’ instructions. After blocking with low-fat dry milk (5% w/v) the 
blot membrane was incubated overnight with a specific polyclonal 
rabbit anti-PGHS-I antibody [I91 or a polyclonal anti-PGHS-2 anti- 
body generated by immunizing rabbits with a synthetic l7-mer peptide 
derived from a unique inserted region of murine PGHS-2 protein near 
the carboxyl-terminal, which is not present in PGHS-I [20]. Blots were 
incubated with a goat anti-rabbit alkaline phosphatase conjugate. 
Color development at the sites of bound complexes was performed 
with Nitrobluc tetrazolium and 5-bromo-4-chloro-3-indolyl phos- 
phate [2l]. As a control for non-specific binding of the second anti- 
body, membranes were incubated without the specific antibodies. The 
stained bands were quantitated by laser densitometry. 
Northern blot analysis of total cellular RNA using the 1,156.kb 
EcoRI fragment from the 5’-end of the mouse PGHS-2 cDNA labeled 
with P-32 by random priming [22] was performed as previously de- 
scribed [I 51. 
Northern blot analysis using the 2.3-kb coding sequence of the ovine 
PGHS-1 cDNA or the 2,767-kb PGHS-I cDNA from mouse labeled 
with digoxigenin by in vitro transcription was essentially performed 
as described by the manufacturer (Boehringer Mannheim). Fluoro- 
graphs and chemiluminographs were analyzed by densitometry. 
3. RESULTS AND DISCUSSION 
The kinetics of the TPA effect on PGHS expression 
in U937 cells were studied by Northern and Western 
blot analysis. In Figs. 1 and 2 the differentiation-associ- 
ated changes in the levels of PGHS-1 and -2 proteins 
and mRNAs are quantitated and plotted. 
3.1. Regulation of PGHS-I protein and tnRNA levels 
Polyclonal antiserum against the murine PGHS-1 
specifically recognizes a 70-kDa polypeptide, which was 
slightly expressed in untreated U937 control cells. 
Treatment with 5 nM TPA led to a steady increase in 
PGHS-1 resulting in a 13-fold induction after three 
days. Similar results obtained in promonocytic THP-1 
cells [13] suggest that this induction generally occurs 
during monocytic differentiation. 
Murine and ovine PGHS-1 probes hybridized to 2% 
and 5.5-kb mRNA species. Similar transcripts were also 
observed in human umbilical vein endothelial (HUVE) 
cells [l 11, erythroleukemia (HEL) cells [23], and in plate- 
let and placenta samples [24], and were speculated to be 
splicing variants [23]. Similar to the occasional detec- 
tion of the 5.5-kb PGHS-1 mRNA species in HEL cells 
[23], the expression pattern of the 5.5-kb PGHS-1 
mRNA species was not as reproducible as that of the 
2.8-kb transcript. At present. the significance and mech- 
anism of generation of heterogeneity of PGHS-1 tran- 
scripts are not known. When normalized with respect 
to the ethidiumbromide fluorescence of the 28 S rRNA, 
the 2.8-kb PGHS-1 mRNA level in U937 cells was virtu- 
ally unaffected by TPA (Fig. 1). The differences in the 
PGHS-1 expression at the protein and mRNA levels are 
discussed below. 
3.2. Regulation of PGHS-2 protein and mRNA levels 
Using the polyclonal antibody against a synthetic 
PGHS-2-specific peptide a double band at about 85 
kDa appeared weakly after 16 h and could be strongly 
detected after 64 h of incubation with TPA (Fig. 2). The 
molecular weight of the human PGHS-2 has been deter- 
mined by in vitro translation to be 70 kDa [l 11. A lack 
of posttranslational modifications of PGHS-2 in rabbit 
reticulocyte lysates might account for this discrepancy. 
The nature of the 85-kDa PGHS-2 doublet, which was 
also found in LPS-primed rabbit alveolar macrophages 
at approximately 72 kDa [20], remains to be elucidated. 
The ovine PGHS-2 cDNA probe hybridized to a 5.3- 
kb mRNA species clearly distinct from the 5.5-kb 
PGHS-1 transcript. Similar PGHS-2 transcripts have 
also been described in other human cells such as mon- 
ocytes [lo] or endothelial cells [l 11. The PGHS-2 
mRNA was not detectable in untreated U937 control 
cells, however highly significant induction occurred 
after one day. In addition, a transient induction of 
PGHS-2 mRNA occurred shortly after the onset of in- 
cubation with TPA (Fig. 2). This effect was observed as 
early as 30 min after addition of TPA (data not shown) 
suggesting that the protein kinase C pathway might be 
involved in the transcriptional regulation of this gene. 
The more pronounced differentiation-associated upreg- 
ulation starting after one day of incubation presumably 
reflects a more complex interplay of different control 
mechanisms arising as part of the differentiation proc- 
ess. Remarkably, the rapid induction of PGHS-2 
mRNA expression is not reflected by detectable early 
increase in expression at the protein level (Fig. 2). The 
small extent of the early mRNA induction relative to the 
late upregulation could account for the lack of detecta- 
ble PGHS-2. Furthermore, it is interesting to note that 
the strong increase in the level of PGHS-2 measured 
after 64 h appeared approximately one to two days after 
the late effect of TPA on PGHS-2 mRNA. Therefore. 
TPA might induce additional posttranscriptional regu- 
latory events. 
3.3. Elf&s of glucocorticoid hormone 
Dexamethasone, which almost completely sup- 
pressed the induction of PGHS activity in TPA-treated 
U937 cells [ 151, completely inhibited the upregulation of 
PGHS-2 protein and mRNA (Fig. 2). The rapid tran- 
sient induction of PGHS-2 mRNA was only prevented 
when dexamethasone was added 4 h prior to TPA (data 
without preincubation not shown). Thus, the activated 
39 
Volume 320, number 1 FEBS LETTERS March 1993 
24 
22 1 5 0 2 4 16 S 0 25 25* LO 40*6L 64* 
20 -- 8OkDo - WV”. m -C..““lb”_, 
$ 18 I PGHS-1 
z 
iij 14 
512. 
Et 
Y 
lo- 
F 8~ 
4 
w 8-- 
u _. 
4 __-- 
__*--- 
__-- 
2 ~- 
TPA 
TPA/Dex* 
0 ’ 
A 
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 
TIME (HOURS) AFTER ADDITION OF TPA OR TPA/DEX 
‘Oi 
8 
id 
4 i- 
0 2 ick ~*1616*&Io6&64* 0253035 
28srfm - -2eSrRNA 
FGHS-1 
l TPA 
---c---________ _____--------. TPA/Dex* 
0 I I I / I 1-l I I I I I 
B 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 
TIME (HOURS) AFTER ADDITION OF TPA OR TPA/DEX 
Fig. 1. Expression of PGHS-1 mRNA and protein in U937 cells. (A) U937 cells were treated with TPA at 5 nM or (*) preincubated with 
dexamethasone (Dex.. I PM) for 4 h and then treated with 5 nM TPA for the indicated times. Cytosol and membranes were prepared by differential 
centrifugation. Microsomal protein (50 ,LL~ [PGHS-I] and 100 pg [PGHS-2. see Fig. 21) was subjected to Western blot analysis as described. The 
stained bands were quantitated by densitometry. S, molecular weight standard. (B) Total RNA (lOpug per lane) from U937 cells treated as described 
in (A) were analyzed by Northern blot hybridization using an ovine digoxigenin-labeled PGHS-I RNA probe essentially as described by the 
manufacturer (Boehringer Mannheim). The same results were obtained using a murine PGHS-1 RNA probe (data not shown). The signals wet-c 
quantitated by densitometry and normalized with respect to ethidiumbromide-stained ribosomal RNA. Data are representative for two independent 
experiments. 
glucocorticoid receptor does not seem to be directly 
involved in regulating PGHS-2 gene expression early 
after addition of TPA to U937 cells. 
The effect of dexamethasone on PGHS-1 expression 
was less pronounced. It reduced the PGHS-1 mRNA 
level by about 75% and inhibited the TPA-induced 
upregulation of PGHS-1 protein by about 65%. The 
association of the total inhibition of PGHS-2 protein 
and mRNA induction with the nearly complete suppres- 
sion of the upregulation of PGHS activity by dexa- 
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Fig. 2. Expression of PGHS-2 mRNA and protein in U937 cells (A) [ see legend of Fig. 1 A] (B) [see legend of Fig. 1B for the conditions]. Northern 
blot analysis using the 1.156-kb mouse cDNA fragment was performed as previously described [ 151. The right panel of the inserted Huorographs 
represents two separate experiments performed to define the time course of PGHS-2 induction with improved resolution. The signals of the left 
inserted panel were quantitated by densitometry. normalized with respect to ethidiumbromide-stained ribosomal RNA and plotted. 
methasone suggests that upregulation of PGHS activity 
in TPA-treated U937 cells is largely due to induced 
PGHS-2 expression. 
Regarding the highly significant induction of PGHS- 
2 mRNA and the negligible increase in 2.8-kb PGHS-1 
mRNA, one is tempted to conclude that PGHS-2 is the 
predominant isoform mediating the differentiation-as- 
sociated upregulation of PGHS activity in U937 cells. 
On the other hand. Western blot analysis reveals that 
there is no quantitative correlation in the TPA or dex- 
amethasone effects on the PGHS-1 mRNA level and 
polypeptide expression. Although the level of the 
PGHS-1 mRNA is not affected by TPA, the 70-kDa 
PGHS-1 protein is induced nearly 5-fold. Furthermore. 
despite the reduction in PGHS-1 mRNA expression 
dexamethasone did not completely prevent the increase 
in PGHS-1 polypeptide level. The underlying posttran- 
scriptional control mechanisms remain to be character- 
41 
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ized. Thus, examination of PGHS- 1 transcript levels are 
likely to be insufficient to estimate the contribution of 
PGHS-1 enzyme to the overall PGHS activity. There- 
fore, the hypothesis that PGHS-2 predominantly medi- 
ates the inflammatory response [lo] supported by corre- 
lations in PGHS activity and PGHS-2 mRNA level in 
LPS-treated monocytes [l 11, should be tested by exam- 
ining PGHS-1 and -2 protein levels. The development 
of PGHS isoform-specific inhibitors should enable the 
determination of the relative contributions of both syn- 
thase isoforms in these systems. In summary, these data 
indicate that the expression of both PGHS-1 and 
PGHS-2 is increased during TPA-induced monocytic 
differentiation of U937 cells in a glucocorticoid-sensi- 
tive manner. This suggests that both isozymes, but pre- 
dominantly PGHS-2, contribute to the concomitant in- 
crease in the capacity to secrete prostanoids. 
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